Deep Track Capital, LP
13F filer · CIK 0001856083Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$6.87BU.S. long equity reported on 13F
Positions6618 new · 14 closed
Net flow last quarter+$655MBuys minus sells
Top 10 positions weight39.6%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202666 positions | |||||
| $509M | 7.41% | 2.54% | +1.7% | Q2 2023 | |
| $360M | 5.24% | 4.53% | -19.0% | Q4 2021 | |
| $254M | 3.70% | 2.22% | +10.8% | Q1 2023 | |
| $250M | 3.64% | 2.97% | Not reported | Q1 2025 | |
| $248M | 3.61% | 0.62% | Not reported | Q1 2022 | |
| $246M | 3.58% | 4.79% | +300.0% | Q1 2026 | |
| $231M | 3.36% | 8.47% | +1.9% | Q1 2025 | |
| NNUVLNuvalent, Inc. | $220M | 3.21% | 56.99% | +29.6% | Q4 2023 |
| $210M | 3.05% | 2.39% | +11.4% | Q1 2023 | |
| $193M | 2.81% | 8.97% | Not reported | Q4 2023 | |
| $189M | 2.75% | 1.71% | +187.6% | Q2 2022 | |
| $188M | 2.73% | 7.45% | +21.9% | Q2 2022 | |
| $183M | 2.67% | 3.15% | -5.3% | Q3 2024 | |
| $179M | 2.60% | Not reported | -6.3% | Q1 2026 | |
| $174M | 2.54% | 1.33% | +12.8% | Q4 2022 | |
| $172M | 2.50% | 8.96% | Not reported | Q2 2023 | |
| $172M | 2.50% | 5.57% | -2.6% | Q4 2025 | |
| $171M | 2.49% | 1.34% | -36.4% | Q2 2023 | |
| $155M | 2.26% | Not reported | +54.2% | Q4 2024 | |
| $136M | 1.98% | 9.51% | +9.2% | Q2 2023 | |
| $132M | 1.93% | 7.71% | New | Q2 2026 | |
| $131M | 1.91% | 2.49% | +52.7% | Q3 2025 | |
| $129M | 1.88% | 2.05% | -8.3% | Q1 2026 | |
| $125M | 1.82% | 4.11% | +6.5% | Q4 2025 | |
| BTBCAXBicara Therapeutics Inc. | $122M | 1.77% | 6.22% | +0.9% | Q3 2024 |
| $111M | 1.62% | 6.72% | +7.3% | Q1 2025 | |
| $109M | 1.59% | 3.74% | +128.9% | Q4 2024 | |
| $109M | 1.58% | 11.69% | Not reported | Q3 2025 | |
| $95.6M | 1.39% | 3.61% | -37.2% | Q3 2024 | |
| $89.6M | 1.30% | 5.37% | Not reported | Q4 2021 | |
| $77.4M | 1.13% | 1.17% | +100.0% | Q1 2024 | |
| AATAIAtaiBeckley Inc. | $76M | 1.11% | 3.90% | +20.2% | Q1 2026 |
| $67M | 0.97% | 0.29% | New | Q2 2026 | |
| $66.7M | 0.97% | 6.82% | Not reported | Q3 2024 | |
| $66M | 0.96% | 3.17% | +157.7% | Q4 2021 | |
| $59.6M | 0.87% | 0.56% | -49.1% | Q4 2023 | |
| $58.5M | 0.85% | 9.90% | New | Q2 2026 | |
| $53.6M | 0.78% | 3.76% | +33.3% | Q1 2026 | |
| $49.4M | 0.72% | 6.68% | Not reported | Q1 2023 | |
| $49.3M | 0.72% | 8.08% | Not reported | Q3 2025 | |
| $48.1M | 0.70% | 2.35% | New | Q2 2026 | |
| $41.2M | 0.60% | 2.59% | New | Q2 2026 | |
| $37.2M | 0.54% | 2.96% | 0.0% | Q1 2026 | |
| $35.6M | 0.52% | 3.39% | Not reported | Q1 2026 | |
| $34.3M | 0.50% | 0.97% | +21.8% | Q4 2021 | |
| $33.3M | 0.48% | 0.91% | -25.0% | Q4 2021 | |
| $28.6M | 0.42% | 3.88% | New | Q2 2026 | |
| $27.5M | 0.40% | 6.12% | -7.3% | Q3 2025 | |
| $25.7M | 0.37% | 3.68% | New | Q2 2026 | |
| $25.6M | 0.37% | 1.94% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202662 positions | |||||
| $308M | 5.04% | 2.54% | +19.2% | Q2 2023 | |
| $286M | 4.68% | 5.65% | Not reported | Q4 2021 | |
| $253M | 4.12% | 8.37% | +19.8% | Q1 2025 | |
| $250M | 4.08% | 2.98% | +7.5% | Q1 2025 | |
| $206M | 3.37% | 2.01% | +4.1% | Q1 2023 | |
| $186M | 3.04% | 2.14% | -4.4% | Q2 2023 | |
| APAPLSApellis Pharmaceuticals, Inc. | $182M | 2.98% | 3.54% | -41.5% | Q1 2024 |
| $167M | 2.72% | 8.99% | +143.9% | Q4 2023 | |
| $165M | 2.70% | 6.42% | +45.6% | Q4 2025 | |
| $149M | 2.44% | Not reported | New | Q1 2026 | |
| $146M | 2.39% | 1.18% | +14.7% | Q4 2022 | |
| NNUVLNuvalent, Inc. | $141M | 2.30% | 43.98% | Not reported | Q4 2023 |
| $127M | 2.07% | 2.16% | +79.5% | Q1 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $125M | 2.05% | 2.04% | +57.9% | Q4 2021 |
| $119M | 1.95% | 12.16% | +39.0% | Q2 2023 | |
| $104M | 1.70% | 6.99% | -18.1% | Q1 2025 | |
| $99.8M | 1.63% | 4.05% | -5.9% | Q3 2024 | |
| $98.4M | 1.61% | 6.14% | -9.8% | Q2 2022 | |
| $98.3M | 1.61% | Not reported | Not reported | Q4 2024 | |
| $90.6M | 1.48% | 1.12% | -58.8% | Q4 2023 | |
| $89M | 1.45% | 4.19% | +68.4% | Q4 2025 | |
| $82.7M | 1.35% | 11.69% | Not reported | Q3 2025 | |
| $82.3M | 1.34% | 5.80% | -15.2% | Q3 2024 | |
| BTBCAXBicara Therapeutics Inc. | $80.8M | 1.32% | 6.20% | +55.4% | Q3 2024 |
| $67.3M | 1.10% | 9.01% | +65.8% | Q2 2023 | |
| $65M | 1.06% | 0.60% | -50.0% | Q2 2022 | |
| $62.5M | 1.02% | 0.43% | +3.9% | Q4 2024 | |
| $58.2M | 0.95% | 3.80% | -3.6% | Q4 2024 | |
| $57.5M | 0.94% | 1.91% | +12.0% | Q3 2025 | |
| $56.7M | 0.93% | 2.88% | New | Q1 2026 | |
| TPTERNTerns Pharmaceuticals, Inc. | $56.6M | 0.92% | 0.93% | +39.6% | Q2 2023 |
| $47.3M | 0.77% | 4.95% | -2.4% | Q4 2022 | |
| $46.1M | 0.75% | 2.67% | +25.6% | Q2 2023 | |
| $42.6M | 0.70% | 8.00% | +19.0% | Q3 2025 | |
| AATAIAtaiBeckley Inc. | $42.5M | 0.69% | 3.28% | New | Q1 2026 |
| $40.7M | 0.67% | 1.93% | -32.5% | Q4 2024 | |
| $38.5M | 0.63% | 0.59% | +120.7% | Q1 2024 | |
| $36.5M | 0.60% | 2.96% | New | Q1 2026 | |
| $36.3M | 0.59% | 1.21% | -24.5% | Q4 2021 | |
| STSLNOSoleno Therapeutics Inc | $36.1M | 0.59% | 2.09% | +7.9% | Q4 2025 |
| $35M | 0.57% | 6.69% | Not reported | Q1 2023 | |
| $31.6M | 0.52% | 1.34% | New | Q1 2026 | |
| $30.4M | 0.50% | 6.54% | Not reported | Q4 2025 | |
| $29.8M | 0.49% | 6.53% | Not reported | Q1 2024 | |
| $27.3M | 0.45% | 1.36% | -44.8% | Q4 2021 | |
| $26.2M | 0.43% | 6.72% | +26.5% | Q3 2025 | |
| $25.7M | 0.42% | 3.62% | New | Q1 2026 | |
| $24.7M | 0.40% | 6.73% | Not reported | Q1 2022 | |
| ATAPGEApogee Therapeutics, Inc. | $24M | 0.39% | 0.38% | Not reported | Q3 2023 |
| $21.5M | 0.35% | 2.98% | Not reported | Q4 2021 | |
| Q4 2025Reported Feb 13, 202652 positions | |||||
| $293M | 5.22% | 5.67% | +18.5% | Q4 2021 | |
| $286M | 5.10% | 2.14% | -32.6% | Q2 2023 | |
| $286M | 5.10% | 1.93% | -2.5% | Q1 2023 | |
| $246M | 4.39% | 7.06% | +0.1% | Q1 2025 | |
| DTDVAXDynavax Technologies Corp | $242M | 4.31% | 13.39% | Not reported | Q4 2022 |
| $212M | 3.78% | 2.71% | -22.4% | Q4 2023 | |
| $210M | 3.74% | 2.26% | +27.8% | Q2 2023 | |
| APAPLSApellis Pharmaceuticals, Inc. | $195M | 3.47% | 6.12% | -3.1% | Q1 2024 |
| $185M | 3.29% | 3.05% | +33.3% | Q1 2025 | |
| $176M | 3.14% | 8.61% | +7.5% | Q1 2025 | |
| $143M | 2.55% | 4.41% | New | Q4 2025 | |
| $137M | 2.44% | 1.20% | +9153.3% | Q2 2022 | |
| $134M | 2.40% | 1.04% | -55.4% | Q4 2022 | |
| $133M | 2.38% | 6.91% | +16.2% | Q2 2022 | |
| $102M | 1.83% | 7.23% | +3.2% | Q3 2024 | |
| $98M | 1.75% | 3.74% | -32.4% | Q4 2023 | |
| $87.5M | 1.56% | 2.54% | New | Q4 2025 | |
| $78.6M | 1.40% | 2.48% | -53.1% | Q4 2021 | |
| $74.6M | 1.33% | 13.25% | Not reported | Q3 2025 | |
| $69.6M | 1.24% | 3.95% | +11.3% | Q4 2024 | |
| $65.5M | 1.17% | 4.44% | -18.6% | Q3 2024 | |
| $62M | 1.10% | 0.42% | -32.5% | Q4 2024 | |
| $61.3M | 1.09% | 6.65% | +954.8% | Q3 2025 | |
| $60.8M | 1.08% | 8.75% | Not reported | Q2 2023 | |
| $56M | 1.00% | 1.21% | Not reported | Q1 2023 | |
| $51.8M | 0.92% | 1.61% | +32.5% | Q4 2021 | |
| $51.6M | 0.92% | 2.86% | -5.0% | Q4 2024 | |
| $50.6M | 0.90% | 7.63% | -6.7% | Q2 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $50M | 0.89% | 1.34% | Not reported | Q4 2021 |
| STSLNOSoleno Therapeutics Inc | $46.3M | 0.83% | 1.91% | New | Q4 2025 |
| $44.3M | 0.79% | 7.38% | New | Q4 2025 | |
| BTBCAXBicara Therapeutics Inc. | $44M | 0.78% | 4.62% | +7.7% | Q3 2024 |
| $42.9M | 0.77% | 5.08% | -20.9% | Q4 2022 | |
| $39.5M | 0.70% | 6.54% | +95.5% | Q1 2024 | |
| $37.7M | 0.67% | 2.12% | +6.2% | Q2 2023 | |
| TPTERNTerns Pharmaceuticals, Inc. | $31.1M | 0.55% | 0.68% | -89.7% | Q2 2023 |
| $30.9M | 0.55% | 6.74% | Not reported | Q1 2022 | |
| $22.4M | 0.40% | Not reported | +11.8% | Q1 2024 | |
| $21.7M | 0.39% | 1.81% | +68.8% | Q3 2025 | |
| $20.1M | 0.36% | 5.52% | +346.7% | Q3 2025 | |
| $16.4M | 0.29% | 0.46% | -69.5% | Q4 2024 | |
| $16.1M | 0.29% | 0.28% | Not reported | Q1 2024 | |
| $15.2M | 0.27% | 8.58% | +85.4% | Q3 2024 | |
| $10.9M | 0.19% | 8.08% | Not reported | Q2 2024 | |
| $6.23M | 0.11% | 1.43% | New | Q4 2025 | |
| $5.38M | 0.10% | 1.65% | Not reported | Q2 2025 | |
| $4.14M | 0.07% | 7.19% | Not reported | Q4 2023 | |
| $4.09M | 0.07% | 0.45% | New | Q4 2025 | |
| RTRAPTRAPT Therapeutics, Inc. | $3.74M | 0.07% | 0.40% | -85.3% | Q4 2022 |
| $2.28M | 0.04% | 0.25% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 202556 positions | |||||
| $260M | 7.24% | 3.32% | -2.3% | Q2 2023 | |
| $249M | 6.95% | 2.36% | -22.2% | Q4 2022 | |
| $236M | 6.60% | 3.59% | +17.8% | Q4 2023 | |
| ATAKROAkero Therapeutics, Inc. | $190M | 5.30% | 4.99% | +31.5% | Q3 2022 |
| APAPLSApellis Pharmaceuticals, Inc. | $181M | 5.05% | 6.32% | +14.3% | Q1 2024 |
| $178M | 4.98% | 7.07% | +71.4% | Q1 2025 | |
| $157M | 4.38% | 5.57% | +2.4% | Q4 2021 | |
| DTDVAXDynavax Technologies Corp | $156M | 4.36% | 13.40% | -11.6% | Q4 2022 |
| $139M | 3.89% | 6.82% | -16.5% | Q4 2023 | |
| 8ETNB89bio, Inc. | $138M | 3.84% | 6.31% | -1.5% | Q3 2022 |
| $118M | 3.29% | 2.32% | -17.9% | Q1 2023 | |
| $116M | 3.24% | 6.54% | Not reported | Q4 2021 | |
| $114M | 3.18% | 2.75% | -47.1% | Q4 2021 | |
| $109M | 3.05% | 1.79% | +12.3% | Q2 2023 | |
| $108M | 3.02% | 2.31% | +39.5% | Q1 2025 | |
| $102M | 2.86% | 8.21% | Not reported | Q1 2025 | |
| $65.4M | 1.82% | 3.57% | Not reported | Q4 2024 | |
| $62.3M | 1.74% | 0.62% | +33.3% | Q4 2024 | |
| $56.3M | 1.57% | 6.44% | -4.4% | Q4 2022 | |
| TPTERNTerns Pharmaceuticals, Inc. | $56.3M | 1.57% | 8.56% | Not reported | Q2 2023 |
| $56M | 1.56% | 7.88% | -0.1% | Q2 2022 | |
| $55.1M | 1.54% | 7.04% | +43.9% | Q3 2024 | |
| $54.7M | 1.53% | 0.38% | New | Q3 2025 | |
| $52.9M | 1.48% | 13.25% | New | Q3 2025 | |
| $51.7M | 1.44% | 3.01% | Not reported | Q4 2024 | |
| $51.1M | 1.42% | 5.49% | +38.4% | Q3 2024 | |
| $48.2M | 1.34% | 1.56% | -11.1% | Q4 2024 | |
| $45M | 1.26% | 8.19% | -11.0% | Q2 2023 | |
| $41.2M | 1.15% | 2.13% | -35.7% | Q2 2023 | |
| BTBCAXBicara Therapeutics Inc. | $38.3M | 1.07% | 4.44% | Not reported | Q3 2024 |
| $34M | 0.95% | 5.05% | +0.8% | Q3 2023 | |
| CTCDTXCidara Therapeutics, Inc. | $28.7M | 0.80% | 1.02% | +20.0% | Q2 2025 |
| $28.2M | 0.79% | 0.78% | Not reported | Q1 2023 | |
| $25.3M | 0.71% | 1.40% | Not reported | Q4 2021 | |
| $19.7M | 0.55% | 6.99% | -9.1% | Q2 2025 | |
| RTRAPTRAPT Therapeutics, Inc. | $19.4M | 0.54% | 4.54% | Not reported | Q4 2022 |
| $17.9M | 0.50% | 2.40% | -37.5% | Q4 2021 | |
| $17.7M | 0.49% | Not reported | -40.0% | Q1 2024 | |
| $15.3M | 0.43% | 4.37% | -50.9% | Q1 2024 | |
| $14.8M | 0.41% | Not reported | Not reported | Q4 2024 | |
| $12.2M | 0.34% | 1.30% | New | Q3 2025 | |
| $7.19M | 0.20% | 8.08% | Not reported | Q2 2024 | |
| $7.16M | 0.20% | 21.85% | New | Q3 2025 | |
| $6.44M | 0.18% | 0.77% | Not reported | Q3 2024 | |
| $5.89M | 0.16% | 4.63% | -34.6% | Q3 2024 | |
| $5.82M | 0.16% | 0.64% | New | Q3 2025 | |
| $5.54M | 0.15% | 3.66% | New | Q3 2025 | |
| $5.39M | 0.15% | 3.27% | Not reported | Q2 2025 | |
| $4.35M | 0.12% | 7.22% | Not reported | Q4 2023 | |
| $4.19M | 0.12% | 0.97% | -84.8% | Q1 2022 | |
Premium opens every quarter this fund has filed